AMSTERDAM, January 31 Amsterdam MolecularTherapeutics (Euronext: AMT), a leader in the field of human gene therapy,today announced that further to its plan of rotation to appoint independentdirectors to its Supervisory Board, the company will submit the appointmentof Mr. Philippe van Holle, Head of Celgene Europe (NASDAQ: CELG) to itsAnnual General Meeting of shareholders. Mr. Van Holle is expected to replacenon-independent director Raj Parekh of Advent Venture Partners, one of AMT'sshareholders, who will step down. In the course of 2008, AMT expects tosubmit the appointment of several other highly qualified independentdirectors to its shareholders to replace all the current non-independentdirectors. Mr. Van Holle has 30 years of marketing and sales experience inthe pharmaceutical and biotechnology industries. Most notably he wasresponsible at Amgen Europe for the commercial roll-out of Neupogen (R) andEpogen (R), the two first biotech blockbuster products. Subsequently heserved as an executive at Genzyme Europe, overseeing the commercialization ofGenzyme's orphan drugs. In 2005, he joined Celgene as Head of Celgene Europe.Over the past few years Celgene has grown into the fourth largestbiotechnology company worldwide with a market capitalization of approximately$20 billion.
AMT's AGM is scheduled for April 16, and will take place at the Rosarium,Amsterdam, The Netherlands.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to circumventmany if not all of the obstacles that have prevented gene therapy frombecoming a mainstay of clinical medicine. Using adeno-associated viral (AAV)vectors as the delivery vehicle of choice for therapeutic genes, the companyhas been able to design and validate what is probably the first stable andscalable AAV production platform. As such, AMT's proprietary platform holdstremendous promise for thousands of rare (orphan) diseases that are caused byone faulty gene. AMT currently has a product pipeline with six products atdifferent stages of development.
Certain statements in this press release are "forward-looking statements"including those that refer to management's plans and expectations for futureoperations, prospects and financial condition. Words such as "strategy,""expects," "plans," "anticipates," "believes," "will," "continues,""estimates," "intends," "projects," "goals," "targets" and other words ofsimilar meaning are intended to identify such forward-looking statements.Such statements are based on the current expectations of the management ofAmsterdam Molecular Therapeutics only. Undue reliance should not be placed onthese statements because, by their nature, they are subject to known andunknown risks and can be affected by factors that are beyond the control ofAMT. Actual results could differ materially from current expectations due toa number of factors and uncertainties affecting AMT's business, including,but not limited to, the timely commencement and success of AMT's clinicaltrials and research endeavors, delays in receiving U.S. Food and DrugAdministration or other regulatory approvals (i.e. EMEA, Health Canada),market acceptance of AMT's products, effectiveness of AMT's marketing andsales efforts, development of competing therapies and/or technologies, theterms of any future strategic alliances, the need for additional capital, theinability to obtain, or meet, conditions imposed for required governmentaland regulatory approvals and consents. AMT expressly disclaims any intent orobligation to update these forward-looking statements except as required bylaw. For a more detailed description of the risk factors and uncertaintiesaffecting AMT, refer to the prospectus of AMT's initial public offering onJune 20, 2007, and AMT's public announcements made from time to time.
SOURCE Amsterdam Molecular Therapeutics B.V